PharmaForceIQ Strengthens Its Offering through Aktana Acquisition
PharmaForceIQ has officially acquired Aktana, enhancing its position in the pharmaceutical sector. This strategic acquisition merges an innovative digital orchestration platform with an advanced AI-driven field Next-Best-Action (NBA) system, creating a groundbreaking solution designed to optimize customer engagement. The integrated platform promises an improved operational framework for pharmaceutical companies, allowing them to go live with an end-to-end commercial customer engagement system within a mere 6–8 weeks.
This union represents a significant milestone, marking the first fully integrated optichannel solution available in the market. By unifying brand and field strategies, the platform enables corporations to streamline execution and measure their impact in real-time. The combination of PharmaForceIQ's flexible, machine-learning powered platform with Aktana's AI capabilities enhances the scalability and innovative potential of the combined service.
Dramatic Expansion and Enhanced Capabilities
The acquisition significantly expands PharmaForceIQ's reach in the United States while also making strides into various global markets, including LATAM, APAC, and EMEA. This expansion enriches its offerings in field engagement, allowing for deeper predictive insights that aid field teams in becoming more effective in their roles.
Powered by Aktana's exclusive Knowledge Nexus dataset, the NBA platform comprises real-world insights derived from over 85 validated use cases, encompassing more than 100 million field suggestions and 5,000 tactics implemented over a decade of industry expertise. The results from this powerful platform are substantial, showcasing:
Proven Success in Sales Performance
PharmaForceIQ's advanced tools have demonstrated remarkable effectiveness across its client base, leading to:
- 36% increase in new prescription rates (NBRx).
- 19% enhancement in sales performance particularly following competitor product launches.
- A time savings of 20 minutes per day for reps in planning and logging activities.
Leadership Vision and Strategic Direction
Hemal Somaiya, PharmaForceIQ's Chief Executive and Strategy Officer, expressed excitement about the new capabilities, stating, "This acquisition deepens our orchestration engine, confirming PharmaForceIQ as the only end-to-end go-to-market customer engagement platform in the industry. This development allows us to accelerate our efforts across clients and other global pharma companies, empowering teams to be more intelligent and effective while optimizing marketing performance. "
By employing optichannel engagement strategies, PharmaForceIQ is poised to realize significant efficiency gains across its commercial functions, resulting in:
- Triple the average script lift.
- A 22% surge in adherence to brand strategies.
- An impressive 80% rise in rates of healthcare professional (HCP) engagement.
- Cost savings ranging from 20% to 30% compared to conventional media buying practices.
Innovative Platform Enhancement
Derek Choy, PharmaForceIQ's Head of Product and previous Chief Product Officer at Aktana, shared his enthusiasm for the move, stating, "Bringing our Field Orchestration platform into the fold will elevate our product, allowing for unrivaled orchestration capabilities across field and digital channels. Our integrated platform enables teams to delve deeper into customer understanding, forecasting, coordinating, and tracking personalized customer journeys through appropriate fields, digital mediums, and peer-to-peer interactions. "
Over the past two years, Aktana has implemented significant enhancements to its platform, integrating AI-driven communication planning, automated tactic optimization, and strategic visibility to refine the HCP journey. These capabilities will now be further enhanced by the dedicated partnership from a team that has achieved a remarkable 100% client renewal rate.
Moving Forward
As PharmaForceIQ continues to innovate and expand its functionalities, this acquisition is not merely about growth but about redefining how pharmaceutical companies engage with healthcare stakeholders. The future looks bright for PharmaForceIQ as it leads the way for transformative pharmaceutical marketing engagement.
Frequently Asked Questions
What is the significance of PharmaForceIQ's acquisition of Aktana?
The acquisition creates a cutting-edge solution that optimizes customer engagement through AI-driven technologies, enabling faster deployment and improved operational efficiencies.
How will the new platform benefit pharma companies?
The platform consolidates brand strategy with field engagement, enhancing overall effectiveness while providing immediate metrics and insights.
What are the expected improvements after implementing the new system?
Pharma companies can anticipate increased prescription rates, better adherence to marketing strategies, and significant savings on traditional media costs.
What unique features does the Aktana technology offer?
Aktana's technology provides real-world insights and automates many communication and planning tasks, allowing for deeper customer understanding.
How does this acquisition affect PharmaForceIQ's market presence?
The acquisition boosts PharmaForceIQ's capabilities and market reach, particularly in key regions like the U.S., LATAM, APAC, and EMEA, positioning it as a leader in the industry.
